Renee Maria Saliby, Research Fellow at Dana-Farber Cancer Institute, shared on X:
“IO-based doublets have been hard to beat in 1L mRCC.
Triplets don’t seem to be the answer whether by adding a HIF2i or CTLA4i! Drug exposure and tox may be the issue here.
Toni Choueiri continues to push for better SOC! What other strategies could be attempted to improve outcomes for pts in this setting?”
You can also read:
KEYNOTE-564 at ESMO 2026: Final Analysis of Adjuvant Pembrolizumab in Clear Cell RCC
